Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom

NCT ID: NCT00996853

Last Updated: 2018-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9206 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The focus of this study is to assess the safety of GSK's H1N1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data.

This study is a commitment to the European Medicines Agency (EMEA), as part of GlaxoSmithKline Biologicals' (GSK Biologicals') risk management plan for pandemic influenza vaccination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Collaborator: Medicines and Healthcare products Regulatory Agency

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Total vaccinated cohort

The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.

Safety follow up

Intervention Type OTHER

Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Safety follow up

Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent, and assent where appropriate, obtained from the subject/from the subject's parent(s)/ Legally Acceptable Representative(s) (LAR).
* A male or female subject vaccinated with a first dose of GSK Biologicals' H1N1 pandemic influenza vaccine
* shortly (\<24h) before being recruited in the study, and
* within a GP practice participating in the study and where the subject is registered.
* Subjects who the Investigator believes that they and/or their parent(s)/LAR can and will comply with the requirements of the protocol

Exclusion Criteria

* Subjects already vaccinated with any other H1N1 pandemic vaccine before study enrolment.
* Child in care
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Leicester, , United Kingdom

Site Status

GSK Investigational Site

Lichfield, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

Cambridge, Cambridgeshire, United Kingdom

Site Status

GSK Investigational Site

Watford, Hertfordshire, United Kingdom

Site Status

GSK Investigational Site

Canterbury, Kent, United Kingdom

Site Status

GSK Investigational Site

Blackburn, Lancashire, United Kingdom

Site Status

GSK Investigational Site

Wellingborough, Northamptonshire, United Kingdom

Site Status

GSK Investigational Site

Bath, Somerset, United Kingdom

Site Status

GSK Investigational Site

Frome, Somerset, United Kingdom

Site Status

GSK Investigational Site

Addlestone,Surrey, , United Kingdom

Site Status

GSK Investigational Site

Attleborough, Norfolk, , United Kingdom

Site Status

GSK Investigational Site

Axbridge, Somerset, , United Kingdom

Site Status

GSK Investigational Site

Baldock, Herts, , United Kingdom

Site Status

GSK Investigational Site

Balham, London, , United Kingdom

Site Status

GSK Investigational Site

Bath, Avon, , United Kingdom

Site Status

GSK Investigational Site

Bath, Somerset, , United Kingdom

Site Status

GSK Investigational Site

Bedwell Crescent, Stevenage, , United Kingdom

Site Status

GSK Investigational Site

Blenheim Walk, Leeds, , United Kingdom

Site Status

GSK Investigational Site

Botesdale, , United Kingdom

Site Status

GSK Investigational Site

Boughton, King's Lynn, , United Kingdom

Site Status

GSK Investigational Site

Bristol, Avon, , United Kingdom

Site Status

GSK Investigational Site

Bromsgrove,Worcestershire, , United Kingdom

Site Status

GSK Investigational Site

Chard, Somerset, , United Kingdom

Site Status

GSK Investigational Site

Chesterfield, , United Kingdom

Site Status

GSK Investigational Site

Colchester,Essex, , United Kingdom

Site Status

GSK Investigational Site

Comberton,Cambridge, , United Kingdom

Site Status

GSK Investigational Site

Darlington, Co. Durham, , United Kingdom

Site Status

GSK Investigational Site

Devon, , United Kingdom

Site Status

GSK Investigational Site

Didcot,Oxfordshire, , United Kingdom

Site Status

GSK Investigational Site

Doncaster, , United Kingdom

Site Status

GSK Investigational Site

Ecclesfield, , United Kingdom

Site Status

GSK Investigational Site

Ellesmere Port,Cheshire, , United Kingdom

Site Status

GSK Investigational Site

Escrick, York, , United Kingdom

Site Status

GSK Investigational Site

Essex, , United Kingdom

Site Status

GSK Investigational Site

Fleetwood, , United Kingdom

Site Status

GSK Investigational Site

Gosport, , United Kingdom

Site Status

GSK Investigational Site

Hanworth, Feltham, , United Kingdom

Site Status

GSK Investigational Site

Harrogate, , United Kingdom

Site Status

GSK Investigational Site

Harwood, Bolton, , United Kingdom

Site Status

GSK Investigational Site

Hertfordshire, , United Kingdom

Site Status

GSK Investigational Site

High Kelling,Holt,Norfolk, , United Kingdom

Site Status

GSK Investigational Site

Honiton,Devon, , United Kingdom

Site Status

GSK Investigational Site

Hoyland, Barnsley, , United Kingdom

Site Status

GSK Investigational Site

Hurstpierpoint, West Sussex, , United Kingdom

Site Status

GSK Investigational Site

Kent, Sevenoaks, , United Kingdom

Site Status

GSK Investigational Site

Langport, Somerset, , United Kingdom

Site Status

GSK Investigational Site

Kettering,Kettering, , United Kingdom

Site Status

GSK Investigational Site

Kippax,Leeds, , United Kingdom

Site Status

GSK Investigational Site

Lambeth, London, , United Kingdom

Site Status

GSK Investigational Site

Lancashire, , United Kingdom

Site Status

GSK Investigational Site

Lancaster, , United Kingdom

Site Status

GSK Investigational Site

Lutterworth, Leicestershire, , United Kingdom

Site Status

GSK Investigational Site

Mossley, Ashton Under Lyne, , United Kingdom

Site Status

GSK Investigational Site

Nantwich, Cheshire, , United Kingdom

Site Status

GSK Investigational Site

Norwich, Norfolk, , United Kingdom

Site Status

GSK Investigational Site

Norwich, Norfolk, , United Kingdom

Site Status

GSK Investigational Site

Nottingham, , United Kingdom

Site Status

GSK Investigational Site

Orton Goldhay, Peterborough, , United Kingdom

Site Status

GSK Investigational Site

Oxfordshire, , United Kingdom

Site Status

GSK Investigational Site

Paiginton, Devon, , United Kingdom

Site Status

GSK Investigational Site

Radstock, Bath, , United Kingdom

Site Status

GSK Investigational Site

Romsey, Hampshire, , United Kingdom

Site Status

GSK Investigational Site

Rowlands Castle, , United Kingdom

Site Status

GSK Investigational Site

Ruislip, , United Kingdom

Site Status

GSK Investigational Site

Runcorn, Cheshire, , United Kingdom

Site Status

GSK Investigational Site

Salisbury, Hampshire, , United Kingdom

Site Status

GSK Investigational Site

Sedgefield, , United Kingdom

Site Status

GSK Investigational Site

Shipston-on-Stour, Warwickshire, , United Kingdom

Site Status

GSK Investigational Site

Somerset, , United Kingdom

Site Status

GSK Investigational Site

Southbourne, Hampshire, , United Kingdom

Site Status

GSK Investigational Site

Southsea, Hampshire, , United Kingdom

Site Status

GSK Investigational Site

Stowmarket,Suffolk, , United Kingdom

Site Status

GSK Investigational Site

Sunderland, , United Kingdom

Site Status

GSK Investigational Site

Sway, Hampshire, , United Kingdom

Site Status

GSK Investigational Site

Swindon, Wiltshire, , United Kingdom

Site Status

GSK Investigational Site

Tadworth,Surrey, , United Kingdom

Site Status

GSK Investigational Site

Tarporley,Cheshire, , United Kingdom

Site Status

GSK Investigational Site

Thornbury, Bristol, , United Kingdom

Site Status

GSK Investigational Site

Wandsford, Peterborough, , United Kingdom

Site Status

GSK Investigational Site

Wantage, , United Kingdom

Site Status

GSK Investigational Site

Wantage, Oxon, , United Kingdom

Site Status

GSK Investigational Site

Western Approach,Plymouth, , United Kingdom

Site Status

GSK Investigational Site

Westhoughton, Bolton, , United Kingdom

Site Status

GSK Investigational Site

Wiltshire, Westbury, , United Kingdom

Site Status

GSK Investigational Site

Wiltshire, , United Kingdom

Site Status

GSK Investigational Site

Windemere,Cumbria, , United Kingdom

Site Status

GSK Investigational Site

Wokingham, Berkshire, , United Kingdom

Site Status

GSK Investigational Site

York, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Nazareth I, Tavares F, Rosillon D, Haguinet F, Bauchau V. Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study. BMJ Open. 2013 Feb 5;3(2):e001912. doi: 10.1136/bmjopen-2012-001912. Print 2013.

Reference Type BACKGROUND
PMID: 23388195 (View on PubMed)

Tavares F, Nazareth I, Monegal JS, Kolte I, Verstraeten T, Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine. 2011 Aug 26;29(37):6358-65. doi: 10.1016/j.vaccine.2011.04.114. Epub 2011 May 17.

Reference Type BACKGROUND
PMID: 21596080 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

113585

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.